Adap­ti­m­mune looks to sal­vage ovar­i­an can­cer study by adding flu­dara­bine to prep pa­tients

The use of flu­dara­bine was fin­gered as a key cul­prit in the deaths of sev­er­al pa­tients tak­ing Juno’s lead CAR-T ther­a­py, but it’s an ab­solute­ly vi­tal part of the pre­con­di­tion­ing reg­i­men be­ing used to pre­pare pa­tients for the wave of new cell ther­a­pies now in the clin­ic for can­cer. And Adap­ti­m­mune $ADAP helped un­der­score just how crit­i­cal it is to­day, say­ing that it’s read­just­ing its tri­al pro­to­col for its T-cell ther­a­py for ovar­i­an can­cer, adding flu­dara­bine to the com­bi­na­tion af­ter fail­ing to get any ini­tial re­spons­es in pa­tients with­out it.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER